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ABSTRACT
The vacuolar H+ ATPase (V-ATPase) is a proton pump responsible for acidification 
of cellular microenvironments, an activity exploited by tumors to survive, proliferate 
and resist to therapy. Despite few observations, the role of V-ATPase in human 
tumorigenesis remains unclear. 
We investigated the expression of ATP6V0C, ATP6V0A2, encoding two subunits 
belonging to the V-ATPase V0 sector and ATP6V1C, ATP6V1G1, ATPT6V1G2, ATP6V1G3, 
which are part of the V1 sector, in series of adult gliomas and in cancer stem cell-
enriched neurospheres isolated from glioblastoma (GBM) patients. ATP6V1G1 
expression resulted significantly upregulated in tissues of patients with GBM and 
correlated with shorter patients’ overall survival independent of clinical variables. 
ATP6V1G1 knockdown in GBM neurospheres hampered sphere-forming ability, 
induced cell death, and decreased matrix invasion, a phenotype not observed in GBM 
monolayer cultures. Treating GBM organotypic cultures or neurospheres with the 
selective V-ATPase inhibitor bafilomycin A1 reproduced the effects of ATP6V1G1 siRNA 
and strongly suppressed expression of the stem cell markers Nestin, CD133 and 
transcription factors SALL2 and POU3F2 in neurospheres. 
These data point to ATP6V1G1 as a novel marker of poor prognosis in GBM 
patients and identify V-ATPase inhibition as an innovative therapeutic strategy for 
GBM.
INTRODUCTION
V-ATPase is a ubiquitously expressed and 
evolutionary conserved multimeric proton pump that 
acidifies intracellular compartments and the extracellular 
milieu. V-ATPase is composed of a membrane-spanning 
V0 sector regulating proton permeability and a V1 
sector providing ATPase activity for V0 rotation relative 
to membranes. Pumping efficiency is modulated by 
regulated assembly of the two sectors and by coupling of 
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ATPase activity with V0 rotation [1]. Multiple roles have 
been attributed to V-ATPase in physiological conditions, 
among which regulation of pH balance, control of 
neurotransmitter trafficking and degradation of membrane-
bound proteins are the most important [1, 2]. In addition, 
recent evidence indicated that V-ATPase acts directly in 
the endolysosomal compartment to modulate signaling 
pathways important for development that are dysregulated 
in cancer, such as Notch, Wnt or mTOR signaling [3-
7]. This evidence, together with the fact that a variety 
of human tumors display overexpression of V-ATPase 
subunits, suggests that V-ATPase might play a crucial, 
albeit largely unexplored, role in supporting tumorigenesis. 
So far, overexpression of V-ATPase in human tumors has 
been associated to invasive and chemoresistant phenotypes 
[8, 9] and to increased proliferative activity [10, 11, 12]. 
Cancer cells are characterized by an abnormal basic 
intracellular microenvironment, and such pH imbalance 
has been proposed to sustain survival by limiting 
apoptosis, ultimately enhancing cancer proliferation [11]. 
Thus, V-ATPase could in principle represent a novel target 
for anti-neoplastic approaches [13-16]. 
Gliomas are the most frequent primary brain cancers 
in adults characterized by poor prognosis and limited 
therapeutic options. Temozolomide, an alkylating agent 
representing the standard of care, is not curative and 
overall mortality rates are high [17, 18]. To date, histologic 
classification is the most significant prognostic factor in 
predicting patient survival. Molecular features, including 
methylation of O6-methylguanine-DNA methyltransferase 
(MGMT) promoter, isocitrate dehydrogenase 1 or 2 
(IDH1/2) gene mutations or 1p/19q chromosomal loci 
deletion have recently provided additional information. 
Nevertheless, limited improvement in prognosis has been 
achieved, especially in adult patients or for high grades 
tumors [19, 20]. 
Dysregulated ion balance in glioma stem cells is 
emerging as a key factor that could contribute to rapid 
and aggressive tumor formation and relapse [18]. In line 
with this evidence, increased expression and/ or activity 
of V-ATPase, or of other ion transporters is observed 
in almost all cancers [11, 15, 18, 21-23]. Therefore 
understanding of oncogenic mechanisms depending on 
selective ion transport could lead to more promising and 
tailored therapeutic approaches. On these premises, the 
goal of this study was to determine whether V-ATPase is 
dysregulated in glioma stem cells and to assess whether 
V-ATPase targeting could represent an innovative strategy 
for GBM therapy. 
RESULTS
V-ATPase subunit G1 is up-regulated in human 
gliomas and in GBM neurospheres
To get insights on the involvement of V-ATPase 
dysregulation in human gliomas, we evaluated a panel of 
V-ATPase subunits belonging to either the V0 (ATP6V0C, 
ATP6V0A2) or the V1 (ATP6V1C, ATP6V1G1, 
ATPT6V1G2, ATP6V1G3) sectors (Supplementary 
Figure 1) using Oncomine, a web-based repository of 
publicly available series of glioma patients. This analysis 
showed that ATP6V1G1 and ATP6V0A2 are frequently 
over-expressed in gliomas compared to non-neoplastic 
brain tissues without concomitant up-regulation of other 
subunits (Supplementary Figure 2A, 2B). Available 
brain cancer series were also investigated for V-ATPase 
gene amplification. Significant copy number gain for 
ATP6V1G1 gene located at 9q32 was detected only in 
recurrent GBMs and not in primary tumors, possibly 
suggesting that gene amplification might be a later event 
secondary to gene overexpression (Supplementary Figure 
2C).
To confirm these in silico findings in an experimental 
set-up, we assayed V-ATPase expression at gene or protein 
expression levels in a small cohort of brain tumors (Gene 
expression series; Table 1). Among the V-ATPase subunits 
analyzed, ATP6V1G1 (V-ATPase G1) was the most 
expressed in human gliomas (Figure 1A and 1B), whereas 
expression of the V-ATPase G1 paralog ATP6V1G3 
was absent in all cases and therefore was excluded from 
further analysis. Interestingly, ATP6V1G1 expression was 
also high in commercially available GBM cells (LN229 
and T98G) compared to a less aggressive line (SW1088; 
Supplementary Figure 3A, 3B), and in high-grade human 
glioma tissues compared to grade II tumors (Figure 1C). 
Next, to identify whether V-ATPase subunit 
expression could be elevated in cancer stem cell enriched 
samples, we analyzed seven primary neurospheres 
obtained from GBM patients (Supplementary Table 
1) for whom the corresponding tumor tissue and the 
differentiated primary cell cultures were available (Figure 
1D). Elevated gene and protein expression of ATP6V1G1 
subunit in neurospheres was detected (Figure 1E, 1F and 
Supplementary Figure 4A). Moreover, ATP6V1G1 gene 
and protein expression significantly decreased when 
GBM neurospheres were differentiated into adherent cell 
monolayers (Figure 1G-1I and Supplementary Figure 
4B-4D). Finally, V1G1 expression was undetectable in 
protein extract of grade I brain tumors (Figure 1H, 1I and 
Supplementary Table 1), whereas it was abundant in rat 
embryonic hippocampal neuronal cells (E18 RHN; Figure 
1H, 1I). These data indicate that V-ATPase G1 expression 
is high in aggressive gliomas and in cancer cell stem cells.
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Figure 1: V-ATPase expression in normal brain or gliomas. A., B. The vacuolar proton pump subunits V1C1, V1G1, V1G2, 
V0A2 and V0C were analyzed by qPCR (A., RQ) or immunohistochemistry (B., IHC score) in a panel of human gliomas (n = 54). °, p 
= 0.03; *, p = 0.02; **, p = 0.002; ***p < 0.0001 by unpaired t tests. Line, mean with SEM. RQ, mRNA relative quantity. C. V-ATPase 
subunits expression was investigated in human glioma tissues classified according to WHO grade II, III or IV (GBM). D. Expression of 
the indicated V-ATPase subunit was analyzed by immunofluorescence in primary glioma tissues and derived neurosphere or differentiated 
(monolayer) cell cultures from seven individual patients. Representative images are shown. E. Glioblastoma neurospheres obtained from 
individual patients (n = 7) were analyzed for differential gene expression of V-ATPase subunits compared to their original tumor tissues. 
Bars, mean±SD. F. GBM neurospheres obtained from 5 individual patients were analyzed for V-ATPase subunit V0A2, V1C1 and V1G1 
protein presence by western blotting. Vinculin (Vinc.) was a loading control. G. Quantification by qRT-PCR of ATP6V1G1 mRNA level in 
GBM neurospheres or differentiated cultures obtained as in Supplementary Figure 4B (n = 5 patients). H. V-ATPase G1 protein expression 
was analyzed by western blotting in matched GBM neurospheres and differentiated cell monolayers, cultures obtained from Grade I brain 
tumors (GradeI#1 and #2), and embryonic rat hippocampal neural cells (E18 RHN). Vinculin (vinc.) was a loading control. I. Quantification 
of V-ATPase G1 protein expression obtained as in H was performed with Image J. *, p = 0.03 by Wilcoxon signed rank test comparing 
matched neurosphere and differentiated cultures.
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Table 1: Demographic and clinicopathological characteristics of the glioma patients’ series.
Table 2: Multivariate analysis. Overall survival (OS) was analyzed in GBM patients according to the indicated covariate2 
using the Cox Proportional-Hazards regression model
Oncotarget17518www.impactjournals.com/oncotarget
V-ATPase G1 is a marker of poor prognosis for 
GBM
We next evaluated whether V-ATPase G1 was 
significantly enriched in GBM and if was correlated to 
GBM patients’ clinical features or prognosis. Therefore 
we analyzed V-ATPase G1 immunoreactivity in a larger 
set of primary gliomas arranged in tissue microarrays 
(TMAs) derived from 187 patients and in 85 normal 
brain counterparts (Tissue microarray series; Table 
1). Generally, V-ATPase G1 was significantly more 
abundant in tumor tissues compared to normal cerebral 
parenchyma (Figure 2A, 2B) and GBM displayed the 
highest immunoreactivity compared to oligodendroglioma 
(OD; p < 0.0001), anaplastic OD (AO; p < 0.0001), 
astrocytomas (Ast; p < 0.0001) or anaplastic astrocytomas 
(AA; p = 0.01) (Figure 2B). In normal brain or low-
grade oligodendroglioma samples, V-ATPase G1 was 
expressed by endothelial cells (arrowheads in Figure 
2A). Conversely, in grade III gliomas or GBMs the 
pump subunit was predominantly localized in tumor cells 
(Figure 2A). In regards to clinical features of gliomas 
(Table 1), V-ATPase G1 was more expressed by tumors 
wild-type for IDH1 enzyme (Figure 2C) whereas it did not 
correlate to MGMT promoter methylation (Supplementary 
Figure 5). To investigate whether V-ATPase G1 expression 
could be used as a prognostic marker, we established a 
cut-off to sort patients into low- and high-V-ATPase G1 
expressing categories using ROC curves (Figure 2D 
and Supplementary Figure 6). According to this cut-off, 
corresponding to an immunohistochemistry score of 21.5, 
GBM patients with high V-ATPase G1 expression had the 
worst outcome (Figure 2E, 2F and Supplementary Table 
2). More importantly, multivariate analysis identified 
V-ATPase G1 expression as a predictor of shorter overall 
survival for GBM patients, independent of clinical or 
molecular features of disease (p = 0.005 by Cox regression 
analysis; Table 2). 
ATP6V1G1 depletion or V-ATPase inhibition 
selectively decrease viability of primary GBM 
neurospheres
Prompted by the up-regulation of V-ATPase G1 
in GBM, we next asked whether knock-down affected 
proton pump function and cells viability. To address this, 
we used different GBM models, including LN229 GBM 
cells, primary GBM monolayer cultures differentiated 
from neurospheres or patients’ derived neurospheres 
(Supplementary Figure 4). Transient ATP6V1G1 silencing 
by siRNAs or esiRNA (Figure 3A and Supplementary 
Figure 7A) effectively decreased protein (Figure 3B) and 
mRNA levels while expression was not affected by the 
knock-down of other V-ATPase subunits (Figure 3C and 
Supplementary Figure 7B). Interestingly, ATP6V1G1 
silencing was sufficient to impair V-ATPase-mediated 
acidification of lysosomes in GBM neurospheres (Figure 
3D). In contrast, in differentiated GBM monolayer or 
LN229 cultures ATP6V1G1 knock-down marginally 
reduced lysosomal pH and lysosomal degradation 
(Supplementary Figure 7C, 7D). Depletion of ATP6V1G1 
decreased average neurosphere areas (Figure 3E), 
induced apoptosis (Figure 3F and Supplementary Figure 
8A), and activated effector caspase 3 and 7 (Figure 3G 
and Supplementary Figure 8B). Cell death triggered by 
V1G1 depletion did not involve the Bcl2 pro-apoptotic 
member Bax and did not significantly alter the cell cycle 
(Supplementary Figure 8C, 8D, respectively). Importantly, 
V1G1 depletion decreased neurosphere invasion through 
matrigel (Figure 3H) independently of caspases activity 
(Figure 3H, +ZVAD samples).
 In contrast, in adherent glioma cultures or 
LN229 cells, cell death, caspase 3/7 activity or cell 
cycle transition was not affected by ATP6V1G1 levels 
(Supplementary Figure 9A-9F). Cell motility of LN229 
cells after ATP6V1G1 knock-down was modestly impaired 
(Supplementary Figure 9G, 9H), with a reduction of 
invaded cells of about 30% (Supplementary Figure 9H), 
whereas cell invasion was not impaired by V1G1 depletion 
in differentiated GBM cultures (Supplementary Figure 9I). 
Finally, we monitored sphere-forming ability of primary 
GBM cells transfected with a control, an ATP6V1G1-
directed siRNA or esiRNA over a period of 72 hours. 
ATP6V1G1 depletion severely restrained formation of 
neurospheres, compared to control transfected or untreated 
samples (Figure 4A and Supplementary Movies). As 
expected [18], GBM neurospheres from different patients 
displayed heterogeneous clonogenic potential (Figure 4B). 
We therefore analyzed whether V-ATPase G1 levels were 
correlated with spheres clonogenicity also in response 
to ATP6V1G1 gene knockdown. Remarkably, V1G1 
was more enriched in GMB patients with higher sphere-
forming ability (Figure 4B, 4C), and a lower ATP6V1G1 
gene expression level (GBM#27 and 53 samples) was 
associated to reduced effect of V1G1 knockdown on 
sphere-forming ability of GBM cultures (Figure 4D).
Spurred by the effects of V-ATPase G1 knock-down 
on GBM samples, we explored inhibition of V-ATPase 
activity with the selective inhibitor bafilomycin A1 
(BafA1), as a strategy to hamper GBM cell viability. Acute 
treatment (48 hours) of GBM neurospheres or monolayers 
with different concentrations of BafA1 (20nM-5µM 
range) strongly reduced lysosomal acidification (Figure 
5A, Supplementary Figure 10A, 10B). This effect was 
accompanied by a significant reduction of neurospheres 
area (Figure 5B). Quantification of DNA content in 
neurospheres treated with BafA1 revealed that toxicity 
progressively increased with the drug concentration, with 
approximately 25% of the cells in sub-G1 phase upon 
acute treatment with 5µM BafA1 (Figure 5C, 5D). As 
determined by annexin V staining, apoptosis was activated 
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Figure 2: V-ATPase subunit G1 is a novel marker of poor prognosis in GBM patients. A., B. A glioma tissue microarray 
comprising 85 cores of normal brain parenchyma was analyzed for V-ATPase G1 expression by immunohistochemistry (IHC) A. 
Photomicrographs representing V-ATPase G1 immunoreactivity in normal brain tissue or in the indicated glioma histotype. Arrowheads 
indicate brain endothelium. B. V-ATPase G1 IHC score was obtained by multiplying the percentage of positive cells (range 0-100%) 
and the staining intensity (range: 0-3). According to this score, normal brain was almost negative (median IHC score 0; range: 0-10). 
Oligodendrogliomas (OD; median IHC score 1.75; range: 0-62.5), anaplastic OD (AO; median IHC score 6.1; range: 1.5-67.5), astrocytomas 
(Astr; median IHC score 6.2; range: 0.25-85), anaplastic astrocytomas (AA; median IHC score 11.75; range: 1-185) displayed higher 
V-ATPase G1 expression compared to normal brain. #, p = 0.0004; §, p = 0.047; °, p = 0.038; §§, p = 0.005; §§§, p < 0.0001 by unpaired t-test 
with Welch’s correction, respectively. GBMs scored the highest expression for the subunit G1 (median IHC score 70.25; range: 0.5-260) 
compared to normal brain (§§§, p < 0.0001) and to lower grades gliomas (**, p = 0.012; ***, p < 0.001 by unpaired t-test with Welch’s 
correction). C. V-ATPase G1 expression according to R132H mutation of IDH1 gene in different glioma histotypes. Bars, mean±SEM. *, 
p = 0.01; **, p = 0.009 by unpaired t-test. IDH1-WT or M, absence or presence of R132H mutation; D. ROC curve was used to identify a 
cut-off of V-ATPase subunit G1 IHC score (indicated by a red triangle) for patients’ categorization into low- or high-expressors. AUC, Area 
under curve. 95% CI, 95% Confidence Interval. E., F. Time to progression (TTP, E) or overall survival (OS, F) end-points were evaluated 
in GBM patients according to V-ATPase G1 level using the Kaplan-Meier method. P values are from Log-rank test. HR, Hazard Ratio; CI, 
Confidence Interval.
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Figure 3: V-ATPase subunit G1 is central for GBM stem cell viability and invasive potential. A. Optimization of ATP6V1G1 
transient knockdown in neurospheres by small interfering RNA (siRNA) was performed with three different targeting siRNAs or with 
esiRNA technology. The small interference RNA #1 (V1G1#1) was then chose for subsequent analyses together with V1G1-directed 
esiRNA unless otherwise indicated. B. Immunoblotting analysis of the indicated V-ATPase subunits in GBM neurospheres left untreated 
(Untr) or silenced with a control (Ctrl) or an ATP6V1G1-directed siRNA. A representative experiment is shown. C. ATP6V1G1 gene 
expression quantification in GBM neurospheres transfected with the indicated siRNA (n = 7). D. Confocal immunofluorescence images of 
live GBM neurospheres transfected with a non-targeting (Ctrl) or an ATP6V1G1-directed siRNA (V1G1) for 48 hours and then incubated 
with LysoTracker Red590 for 10 minutes at 37°C. Maximum intensity projections are shown for a single representative experiment out of 
six repeats. Original magnification x 400. Right, quantification of LysoTracker mean fluorescence intensity. **, p = 0.01 Mann-Whitney 
U test. E. GBM neurospheres were transfected with controls or targeting V1G1 siRNAs or esiRNA and their area was calculated 48 hours 
later. Neurospheres area is expressed relative to untreated cultures. F, G. Apoptosis induction or activation of caspase 3/7 after ATP6V1G1 
knockdown (V1G1 siRNA or esiRNA) was evaluated by Annexin V staining or active caspase 3/7 probe and fluorescence microscopy, 
respectively. Right, Quantification of mean fluorescence intensities (n = 6). Scale bar indicates 100µm. *, p = 0.016; #, p = 0.02 by 
Mann-Whitney U test. H. Neurospheres silenced for ATP6V1G1 or with a scramble molecule (Ctrl) and pre-incubated with the general 
caspase inhibitor Z-VAD-FMK (ZVAD). or its negative control Z-FA-FMK (Control) were subjected to matrigel invasion for 24 hours after 
which invaded cells were stained with toluidine blue and counted. Representative images of an experiment out of six are shown. Insets, 
caspase activation was monitored by CellEvent Caspase 3/7 probe (green) by fluorescence microscopy and quantified as corrected total cell 
fluorescence (CTCF). Data are expressed as percentage of invaded spheres relative to the input. *, p = 0.02; #, p = 0.03; **, p = 0.004 ;§, 
p = 0.01 by Mann-Whitney U test.
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even upon treatment with low dose of BafA1 (Figure 
5E). Altogether, these data suggest that at high BafA1 
doses cell death might occur through both apoptotic and 
necrotic mechanisms. Therefore, to avoid unspecific cell 
death, we used 20nM or 500nM of BafA1 for subsequent 
experiments. Confirming annexin V data and similar to 
what observed for ATP6V1G1 knockdown, BafA1 induced 
activation of Caspase 3/7 at both concentrations (Figure 
5F). Besides inducing programmed cell death, BafA1 
strongly inhibited motility of GBM neurospheres (Figure 
5G). Indeed, calcein AM/ToPro-3 differential staining of 
collagen-invading cells indicated that at 20nM migration 
is impaired in presence of very low level of dead cells, 
suggesting that V-ATPase inhibition might diminish GBM 
stem cells motility independently from cell death (Figure 
5H). 
Finally, impairment of clonogenic potential by 
BafA1 treatment inversely reflected V-ATPase G1 
levels detected in patients’ derived GMB neurospheres 
(Figure 5I; see Figure 4C for V1G1 levels). Conversely 
and strikingly, neither viability of differentiated GBM 
cell cultures (Supplementary Figure 10C-10E) or of 
commercial LN229 and T98G cells (Supplementary 
Figure 10F, 10G), nor motility of differentiated GBM 
cultures (Supplementary Figure 10H) was affected by 
acute treatment with BafA1 at any dose. Overall these 
data indicate that V-ATPase pump function is required 
specifically by GBM neurospheres to preserve their 
tumorigenic potential and their propagating ability. 
Figure 4: V-ATPase G1 levels are associated to clonogenicity of GBM neurospheres. A. The ability of GBM cultures to 
generate neurospheres after specific ATP6V1G1 knockdown (V1G1-siRNA or esiRNA) relative to control sample was evaluated by time 
lapse microscopy for 72 hours. Representative images captured from movies (Supplementary Movies 1-3) at time zero and at harvesting 
are shown. B. GBM neurospheres clonogenic capacity in methylcellulose containing media was analyzed in the indicated samples. Left, 
quantification of spheres containing at least 20 cells. C. V-ATPase G1 gene or protein expression levels in the indicated GBM cultures. 
D. The clonogenic potential of the indicated GBM neurosphere was assessed after V1G1 knockdown by siRNA or esiRNA and compared 
to corresponding controls. *, p < 0.05; **, p < 0.01 by Mann Whitney U test. For all graphs, bars represent mean ±SEM of at least six 
experiments.
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V-ATPase inhibition decrease viability of GBM 
organotypic cultures
To test the feasibility of V-ATPase inhibition in 
experimental set-up closest to the in vivo GBM situation, 
we used patient-derived organotypic glioma cultures 
which preserve the tri-dimensional tissue architecture 
and cellular heterogeneity of the original tumor [24, 
25]. We therefore performed BafA1 treatment in a set of 
eight glioblastoma organotypic cultures (Supplementary 
Table 3), to compare drug effects on glioma viability and 
Figure 5: V-ATPase targeting through bafilomycin A1 abrogates GBM stem cells. A. Confocal immunofluorescence images 
of live GBM neurospheres treated with different concentration of bafilomycin A1 (BafA1) for 48 hours and then incubated with LysoTracker 
Red590 for 10 minutes at 37°C. Maximum intensity projections are shown for a single representative experiment out of six repeats. Original 
magnification x 400. Right, quantification of mean fluorescence intensity. §, p = 0.0004; #, p = 0.0001. B.-F. GBM neurospheres treated with 
different doses of BafA1 for 48 hours were analyzed for dimensions B., DNA content by propidium iodide staining and flow cytometry C., 
D. induction of programmed cell death (Annexin V staining; E.), activation of caspase 3/7 by fluorescent microscopy F., or cell invasion 
through matrigel by direct cell counting G.. *, p = 0.016; #, p = 0.03; °, p = 0.013; §, p = 0.027. For all graphs, bars represent mean ±SEM of 
at least six experiments. H. GBM neurospheres were embedded in collagen and treated as indicated. After 48 h cultures were stained with 
calcein-AM (live cells, green) and ToPro-3 (dead cells, red) and analyzed by confocal microscopy. Right, Quantification of the invasion 
radius and of the live vs dead cells ratio. Bars, mean±SEM (n = 4). *, p = 0.02; **, p = 0.004. I. GBM neurospheres clonogenicity after 
BafA1 treatment was assessed by methylcellulose assay for the indicated cultures. Bars, mean ±SEM (n = 3). All statistics are from Mann-
Whitney U test.
Oncotarget17523www.impactjournals.com/oncotarget
proliferation with the alkylating agent temozolomide 
(TMZ), which is the standard of care for GBM. After 
72 hours, treatment with BafA1 significantly decreased 
glioma proliferation (Ki67 labelling; p = 0.02; Figure 
6A, 6B) and induced apoptosis (cleaved Caspase-3Asp175 
expression; p = 0.03; Figure 6A, 6C) while TMZ had little 
effect (Figure 6A-6C). 
BafA1 and TMZ are known to interfere with 
autophagy, with TMZ inducing autophagosome 
formation and BafA1 blocking autophagosome fusion 
with lysosomes [26]. As previously documented in 
neuroblastoma cells in culture [27], treatment of GBM 
organotypic cultures with BafA1 increased lysosome-
associated membrane protein-1 (LAMP-1) content (Figure 
6D), indicating induction of lysosomal stress. However, 
levels of beclin1, a regulator of autophagosome formation, 
in GBM organotypic cultures treated with BafA1 did not 
change, suggesting that lysosomal stress did not involve 
Figure 6: Bafilomycin A1 treatment decreases cell viability in GBM tissue cultures. Organotypic tissue cultures from eight 
GBMs were treated up to 72 h with different concentration of temozolomide (TMZ) or Bafilomycin A1 (Baf) and tissue proliferation (Ki67 
labeling, A., B.), or apoptosis (Cleaved Caspase-3, A., C.) was scored in each sample relative to uncultured (T0) sample. *, p = 0.03; **, p 
= 0.007 by Mann-Whitney U test. H&E, Hematoxylin and Eosin. D., E. GBM tissue cultures treated as in A were analyzed for lysosomal 
content (LAMP-1, D.) or for expression of the autophagy-related protein Beclin 1 (E.) by immunohistochemistry. Photomicrographs show 
representative GBM cultures. Original magnification x400. Data are presented as mean ±SEM.
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modulation of tumor autophagy (Figure 6E). Therefore, 
our data do not support the possibility that autophagy is 
a mediator of cell death in GBM organotypic cultures 
treated with BafA1. Overall, these data indicate that 
V-ATPase inhibition is more efficient than TMZ treatment 
to reduce viability of GBM tissue. 
Treatment of GBM neurospheres or organotypic 
cultures with BafA1 induces selective stem cell 
depletion and reduces stem cell factors expression
Given the results obtained using BafA1 in GBM 
neurospheres and organotypic cultures, we finally assessed 
whether BafA1 treatment affected stem cells in GBM 
tissue. Using the glioma TMA platform (Table 1) we found 
Figure 7: Bafilomycin A1 reduces stem cell factors expression in GBM organ cultures. A. Nestin immunoreactivity was 
analyzed in GBMs of the tissue micro-arrays and correlated to V-ATPase G1 expression in the same samples. B., C. Short term GBM organ 
cultures were treated as in Figure 6. Nestin presence was assessed after 72 hours and quantified relative to uncultured samples (T0). Original 
magnification x400. Bars, mean±SEM. §, p = 0.018 by Mann-Whitney U test. D., E. The stem cell markers CD133, NESTIN or ATP6V1G1 
(D.) and the neurodevelopmental transcription factors SOX2, OLIG2, SALL2 and POU3F2 (E.) were analyzed at gene expression level by 
qPCR in GBM organ cultures treated as indicated. Each point represents the mean of three cultures. RQ, mRNA Relative Quantity.
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that V-ATPase subunit G1 expression was significantly 
correlated with nestin in GBM (n = 98, p = 0.028; Figure 
7A). In addition, treatment with BafA1, but not with TMZ, 
strongly reduced the number of nestin-positive cells in 
GBM organotypic cultures (Figure 7B, 7C). These data 
were confirmed at the gene expression level. Indeed, GBM 
organotypic cultures treated with the V-ATPase inhibitor 
displayed decreased levels of NESTIN and CD133 
besides showing lesser expression of ATP6V1G1 (Figure 
7D). We also analyzed a panel of transcription factors 
recently associated to GBM stem cell propagation, such 
as SOX2, OLIG2, SALL2 and POU3F2 [28]. While TMZ 
increased their expression in treated cultures, variable 
down-regulation of SOX2, SALL2 and POU3F2 was 
observed in GBM organotypic cultures incubated with 
2μM of BafA1 (Figure 7E). Consistent with the effects 
observed in organotypic cultures, treatment of GBM 
neurospheres, which are known to be enriched in cancer 
stem cells [28], with BafA1 decreased nestin protein 
(Figure 8A) and mRNA levels (Figure 8B), as well as 
expression of stem cell-associated factors CD133, SOX2, 
SALL2 and POU3F2 to different degrees (Figure 8C, 8D), 
while V-ATPase G1 mRNA and protein levels remained 
substantially unchanged (Figure 8D). These data confirm 
that GBM stem cells are highly sensitive to V-ATPase 
inhibition.
DISCUSSION
In this study we show that V-ATPase G1 is a novel 
marker of poor prognosis for glioblastoma patients. 
Notably, V-ATPase G1 levels were predictive of overall 
survival in GBM patients independently of the epigenetic 
silencing of MGMT gene, IDH1 mutation, Karnofsky 
performance score, or patients’ age at diagnosis. Our data 
Figure 8: Bafilomycin A1 repress stemness features of GBM neurospheres. A. Nestin expression was evaluated by confocal 
immunofluorescence in GBM neurospheres incubated for 48 hours with vehicle or different concentrations of bafilomycin A1 and quantified 
in multiple z-stacks by ROI. **, p = 0.007; ***, p = 0.0006 by Mann-Whitney U test. Bars, mean ±SEM (n = 5). Left, Representative 
maximum intensity projection images of neurospheres stained for the indicated antibody. B., C. Gene expression evaluation of ATP6V1G1, 
CD133 and NESTIN, or of transcription factors involved in neurodevelopment and reprogramming (SOX2,OLIG2, SALL2 and POU3F2) 
in GBM neurospheres treated for 48 hours with 20 nM or 500 nM of bafilomycin A1, vehicle (Ctrl), or left untreated (Untr). Each point 
represents the mean of four experiments. RQ, mRNA Relative Quantity. D. V-ATPase G1 protein levels in GBM neurospheres after 
bafilomycin A1 treatment were analyzed by western blot. Vinculin was a loading control.
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reveal that ATP6V1G1 is selectively upregulated in GBM 
stem cells and that targeting of V-ATPase through specific 
gene knock-down or pharmacological inhibition hampers 
GBM viability, tumorigenicity and stem cell factors 
expression. We also demonstrate that V-ATPase inhibition 
by BafA1 is feasible and highly effective in human GBM 
organ cultures, an experimental platform that closely 
mimics the in vivo cancer situation [24, 25]. Given the 
selective exploitation of V-ATPase by glioma stem cells, 
our preliminary evidence suggests that V-ATPase targeting 
could represent an attractive novel therapeutic strategy 
in GBM, a fatal disease with no curative option. Indeed 
the suitability of targeting V-ATPase to eradicate cancer 
stem cells has been previously explored in embryonal 
rhabdomyosarcoma disease [22]. 
Overall, we found that V-ATPase G1 protein is 
progressively overexpressed by high-grade gliomas 
compared to less aggressive grade II tumors, whereas it 
is expressed at low level in normal brain. In our series, 
V-ATPase G1 was not associated to MGMT epigenetic 
status, but increased protein levels were detected in brain 
tumors wild-type for isocitrate dehydrogenase 1 (IDH1) 
enzyme, a known marker of worse prognosis [19], and this 
occurred irrespective of their grade. The oncogenic role of 
IDH1 mutations in gliomas is unclear. Nevertheless, IDH 
enzymes are involved in tumor metabolism and energy 
(NADP+) production [29]. Our findings may suggest that 
a regulatory loop between an acidic microenvironment and 
altered bioenergetics in tumor cells could contribute to 
tumorigenesis. Further work will be needed to understand 
the mechanism behind the correlation between V-ATPase 
and IDH enzymes in glioma cells.
 Little is known about regulation of V-ATPase 
subunits expression during tumorigenesis. A previous 
report indicates that V-ATPase G1 is expressed 
ubiquitously in mouse brain, while its paralog V-ATPase 
subunit G2 is expressed in neurons of the central nervous 
system where it is specifically involved in acidification 
of synaptic vesicles [30]. V-ATPase upregulation has 
been described to induce cell transformation [10], to 
sustain the cancer stem cell niche [22], and as a defensive 
mechanism adopted by cancer cells to escape apoptosis 
induced by anticancer agents [31]. Specifically, V-ATPase 
activity appears to be required by ovarian or breast cancer 
cells to invade and metastasize [15, 23, 32-34], or to 
activate oncogenic signaling [5, 35]. Finally, ATP6V0A 
encoding a specific subunit associated to V-ATPase 
function at the plasma membrane, was found upregulated 
in grade III gliomas [12]. Despite this, the functional 
relevance of the upregulation of V-ATPase subunits 
in human cancer is unclear. However, we showed that 
pharmacologic inhibition of V-ATPase function impact 
tumor viability and GBM stem cell features, suggesting 
a clear requirement for pump activity. In good agreement, 
a recent investigation reported that targeting V-ATPase 
pump activity hampers growth and tumorigenic potential 
of rhabdomyosarcoma CSC [22]. In such system, high 
V-ATPase activity was associated to increased invasive 
ability and reduced sensitivity to chemotherapeutics, 
as previously reported [8, 14, 23]. Interestingly, similar 
to V-ATPase the pH-dependent CLIC-1 channel [36] is 
required for proliferation of GBM stem cells [18, 21], 
suggesting that pH unbalances might contribute to GBM 
stem cell niche maintenance. Altogether, this evidence 
indicates that V-ATPase might control multiple aspects of 
tumor development by mechanisms that await elucidation.
In human brain V-ATPase G1 immunostaining 
strongly resembled nestin pattern in either human glioma 
or normal tissues. In normal brain or grade II gliomas, 
both V-ATPase G1 and nestin localize to endothelial cells 
of blood vessels [37, 38]. Conversely, high-grade gliomas 
displayed V-ATPase G1 and nestin upregulation in tumor 
cells, and expression of both proteins was decreased by 
BafA1. These preliminary data suggest that V-ATPase 
might be involved in acquisition and/or maintenance of 
the GBM cancer stem cell niche. Consistent with this, 
BafA1 has been shown to sensitize glioma stem cells to 
gamma-radiation reducing their viability and ability to 
form neurospheres [39].
Concluding, our results suggest that high levels of 
ATP6V1G1 are a characteristic of GBM stem cells and 
could influence the onset of chemoresistance typical 
of high grades gliomas. Indeed patients with a low 
V-ATPase subunit G1 expression had a longer OS and a 
better response to adjuvant concomitant chemo-radiation 
therapy in terms of time to disease progression. Despite 
increased understanding of the molecular alterations 
that characterize different subsets of high-grade glioma, 
almost all patients face a fatal disease with inadequate 
treatment options. Therefore, there is a crucial need to 
identify proteins that could be effectively targeted [18]. 
In this scenario, we have shed light on a core aspect of 
the cellular machinery that is selectively exploited by 
GBM cancer stem cells, whose activity can be modulated 
pharmacologically. Considering that V-ATPase directed 
drugs are currently under preclinical development [14, 
15], our work constitutes the groundwork for future 
understanding of the antitumor activity of V-ATPase 
inhibition in gliomas. 
MATERIALS AND METHODS
Patients
 For this investigation, two series of patients 
diagnosed with de novo glioma were enrolled at 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico (Milan, Italy). A first series consisted of 
54 patients that underwent surgery between 2013 and 
2014, of which both fresh and archival neoplastic tissue 
Oncotarget17527www.impactjournals.com/oncotarget
could be retrieved for molecular or histological analyses 
respectively (Gene expression series). A second set 
of 187 patients that consecutively underwent surgery 
between 2008 and 2010 was enrolled for retrospective 
investigations on formalin-fixed paraffin-embedded 
tissues (Tissue microarray series) as previously described 
[40]. All patients were treated with surgical resection 
of the lesion and nobody received a merely diagnostic 
procedure. The Institutional Review Board approved 
the study. Gliomas were staged according to the WHO 
classification [41] and clinicopathological or molecular 
characteristics of both patients’ series are described in 
Table 1. Following histological diagnosis, all patients 
affected by high grade gliomas (HGG; grades III and 
GBM) underwent concomitant chemo-radiation therapy 
according to the Stupp’s protocol [42]. Follow-up data 
was available for GBM patients and it consisted of neuro-
oncological assessment and brain MRI with gadolinium 
every 3 months as described [40]. Tumor progression was 
defined according to MacDonald’s criteria [17]. Time 
to progression (TTP) and overall survival (OS) records 
were available for 69 (70%) and 70 (71%) GBM patients, 
respectively. TTP was calculated from surgery to tumor 
progression determined by radiological (brain MRIs) 
procedures, whereas OS was calculated from surgery to 
patients’ death. Follow-up ended in December 2012.
Tissue microarrays (TMAs) of glioma or normal 
brain tissues were created as previously described [43], 
with slight modifications. Detailed procedures for TMAs 
construction and immunohistochemical (IHC) experiments 
are detailed in the Supplementary Information.
Oncomine analysis
Differential V-ATPase subunits expression was 
analyzed in published microarray data sets using a Web-
based data-mining platform (Oncomine; available at 
http://www.oncomine.org/). Relative expression data 
of V-ATPase subunits were collected from brain cancer 
datasets only. The t-statistic for significant comparison is 
provided within the data sets in Oncomine.
Glioblastoma primary cultures and neurospheres
GBM neurospheres or differentiated monolayer 
cultures (Supplementary Figure 4B-4D) were obtained 
as described [18, 44] from seven chemo- and radio-
naïve patients surgically treated at Neurosurgery 
Division (Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico) and histologically diagnosed with 
glioblastoma (WHO grade IV, GBM). Differentiated 
primary cultures were also derived from two patients 
diagnosed with grade I glioma (Supplementary Table 1). 
Post-surgical samples were used after patients’ informed 
consent and Institutional Ethical Committee approval and 
primary cultures were coded as Grade I#1, 2 and GBM 
with case number (Supplementary Table 1). Details of 
this procedure can be found online in the Supplementary 
Information.
Ex-vivo glioma tissue cultures
Glioma tissue slices were obtained from surgical 
waste of eight patients affected by GBM treated at 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinco (Milan, Italy). Written informed consent 
was obtained from all patients. Clinicopathological 
characteristics are described in Supplementary Table 
3. Briefly, precise thick (300 µm) tissue sections 
were generated using a vibratome (VT1200, Leica 
Microsystems, Milan, Italy) as previously described [24, 
25], and cultivated up to 72 hours in presence or absence 
of 100µM or 200µM temozolomide, 0.2µM or 2µM 
bafilomycin A1 (both drugs were from Sigma-Aldrich, 
Milan, Italy). As control sample we used an untreated 
tissue slice cultivated in complete media supplemented 
with vehicle (1 µl of DMSO in 1 ml of media). Culturing 
medium supplemented with drugs or vehicle was 
replaced every 24 h. At harvesting, tissue cultures were 
snap-frozen or formalin-fixed and paraffin-embedded 
(FFPE) for molecular or morphological (hematoxylin 
and eosin staining) and immunohistochemistry analyses, 
respectively. For each glioma culture, tissue proliferation 
(Ki67 labeling), apoptosis (cleaved Caspase-3 Asp175), 
Beclin 1, LAMP-1, Nestin or V-ATPase G1 (clone D-5; 
Santa Cruz Biotech, Santa Cruz, CA, USA) protein 
presence and expression in cultivated tissue slices were 
evaluated by immunohistochemistry (IHC) and scored 
as percentage of positive cells out of the total. IHC 
scores in cultivated tissue slices are expressed relative to 
baseline uncultured sample (T0). Similarly, selected genes 
expression (CD133, NESTIN, ATP6V1G1, POU3F2, 
SALL2, OLIG2, SOX2; Supplementary Table 4) were 
quantified relative to reference gene (18S rRNA) in 
cultured or not samples. Detailed immunohistochemistry 
and gene expression protocols can be found in the 
Supplementary Information.
RNA purification and qPCR
Total RNA was purified from glioma tissues or 
cell cultures using Trizol reagent (Life Technologies 
Inc.) or Master Pure RNA purification kit (Epicentre 
Biotechnologies, Illumina; Madison, WI, USA) following 
manufacturer procedures. Detail of retrotranscription 
or quantitative PCR reactions are provided in the 
Supplementary Information. 
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Cell lines, siRNA transfections and V-ATPase 
inhibition
SW1088, T98G or LN229 glioma cell lines were 
purchased from ATCC (Manassas, VA, USA) and cultured 
as suggested by the manufacturer. Protein extract from 
E18 primary rat hippocampal neurons (E18 RHN) were 
a generous gift from Fabio Grohovaz lab (IRCCS San 
Raffaele Scientific Institute, Neuroscience Division, 
Milan, Italy). GBM primary cultures or commercial 
cell lines were transiently transfected in Optimem 
media using Lipofectamine 3000 (both from Invitrogen, 
Life Technologies Inc.) and 100pM of specific or non-
targeting control siRNAs or esiRNA (all from Sigma 
Aldrich, St. Louis, MO, USA) as described [45]. Three 
ATP6V1G1 siRNAs were initially tested (MISSION 
siRNA SASI_Hs02_00338522; SASI_Hs01_00227261; 
SASI_Hs01_00227268) together with ATP6V1G1-
targeting esiRNA (MISSION esiRNA EHU156241) 
and corresponding non-targeting control (MISSION 
esiRNA EHUEGFP). The siRNA SASI_Hs02_00338522 
(siRNA-V1G1#1) and V1G1-esiRNA were then chosen 
for functional experiments if not otherwise indicated. 
After five hours, transfection mixture was replaced with 
standard culturing media. V-ATPase inhibition was 
achieved treating cultures with different concentrations 
of bafilomycin A1 (BafA1, range 10nM-5µM; Sigma 
Aldrich) or concanamycin A (ConcA, range 50-500nM; 
Sigma Aldrich) for 48 hours. Effect of siRNAs or drugs 
incubation on V-ATPase pump activity was measured 
incubating primary or commercial GBM cultures with 
1 µM of LysoTracker Red (DND-99, Life Technologies 
Inc.) for 10 min or with 1 µM of DQ-Red BSA (Life 
Technologies Inc.) for 1 h, as described [35]. Then cultures 
were rinsed and mounted immediately (Lysotracker) or 
fixed with 4% paraformaldehyde (4% PFA; DQ-BSA) for 
confocal microscopy examination (TCS SP5 Confocal, 
Leica Microsystems, Milan, Italy).
Cell viability assays
LN229 or T98G cell viability after V-ATPase 
inhibition by selective drugs was analyzed after 48 h by 
measuring mitochondrial function through the reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich) as reported [45]. Cell 
cycle transitions and quantification of hypodiploid 
DNA content (i.e. sub-G1 fraction) were determined 
in transfected or drug treated cultures after 48 h, by 
propidium iodide staining and flow cytometry, as 
described [45]. Alternatively, cells were stained with 
Annexin V/PI using the FITC Annexin V Apoptosis 
Detection Kit (BD Bioscience, San Diego, CA, USA), 
evaluated by multiparametric flow cytometry and analyzed 
using FlowJo software. For GBM neurospheres the FITC 
Annexin V Fluorescence Microscopy Kit (BD Bioscience) 
was used and signal intensity was acquired using a 
fluorescence inverted microscopy (DMI4000B, Leica 
Microsystems). Detection of effectors caspase activation 
was performed incubating live cultures with the CellEvent 
Caspase-3/7 Green probe (Life Technologies) and signal 
(at 503nm) or bright-field images were acquired using a 
fluorescence microscope. Details of the procedure can be 
found in the Supplementary Information.
Cell motility and cell invasion
LN229 cells grown in adhesion were transfected 
with ATP6V1G1 siRNA or control molecule for 24 h after 
which 5×104 cells were seeded in serum-free medium on 
collagen- or Matrigel-coated chambers (BD Biosciences) 
to evaluate cell migration or invasion, respectively. For 
GBM neurospheres invasion assay, an average of 13 
spheres per condition (untreated, vehicle, bafilomycin A1-
treated samples or control- and ATP6V1G1 knockdown 
samples) was used. For ATP6V1G1 or control-silenced 
glioma cultures the standard culturing medium was 
used as chemoattractant in the bottom chamber. When 
bafilomycin A1 effect was tested, complete Neurocult 
media (Stemcell Technologies) supplemented with 
the indicated concentration of the drug was used as 
chemoattractant. Cells or neurospheres were allowed to 
migrate or invade for 24 h, as described [45] after which 
cultures present on lower insert surface were fixed with 
methanol, stained with toluidine blue, and quantified by 
direct cell counting using bright-field optical microscopy 
(Leica DMI4000B). For neuropsheres, the number of 
invaded foci was normalized on the original input. GBM 
neurospheres invasion experiment was repeated six times 
in duplicate using six different GBM cultures, whereas 
other motility experiments were performed three times 
in duplicate. When neurospheres were preincubated with 
the general caspase inhibitor Z-VAD-FMK (ZVAD), or 
its negative control inhibitor Z-FA-FMK (Control; both 
from BD Pharmingen), 10µM of the indicated molecule 
was added to the cultures one hour before the seeding on 
matrigel inserts. Effective inhibition of active caspase 3/7 
was analyzed using CellEvent caspase 3/7 fluorescent 
probe (Life Technologies) in parallel plates when matrigel 
inserts were harvested. For analysis of contextual tumor 
cell viability and motility, neurospheres were embedded 
in 600 μl of bovine collagen type I (Sigma Aldrich) in 
24-well plates, overlaid with 1 ml of growth medium 
containing 20nM of bafilomycin A1 or vehicle (DMSO, 
control). After 48 h, neurospheres were analyzed for 
changes in maximum invasion distance (radius) and 
quantification of live versus dead cells was performed 
staining the spheroids with calcein-AM (live, green) 
and ToPro-3 (dead, red; both reagents were from Life 
Technologies) as described [46]. Samples were imaged 
with a HCX PL Fluotar 10X/0.0NA objective using 
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a Leica TCS SP5 confocal microscope, and multiple 
stacks (Z-step = 4µm) were generated in 2 channels. 3-D 
reconstruction of stained neurospeheres was performed 
using Volocity 3D Image analysis software (PerkinElmer, 
Waltham, MA, USA).
Immunofluorescence and time-lapse microscopy
For immunofluorescence experiments, glioma 
monolayer cultures were grown on cover-glasses whereas 
neurospheres were cyto-spinned on charged slides 
(Thermo Scientific, Waltham, MA, USA). Glioma cultures 
were stained with primary antibodies against V-ATPase 
G1 (D5, Santa Cruz Biotechnologies), GFAP (G9269; 
Sigma Aldrich), cleaved Caspase-3 (D175; Cell Signaling 
Technologies, Danvers, MA, USA), Nestin (MAB 1259; 
R&D Systems, Abingdon, UK), Sox2 (D6D9, Cell 
Signaling Technology Inc.), Oligodendrocyte marker O4 
(O7139; Sigma Aldrich), GFAP (G9269; Sigma Aldrich), 
or Tuji1 (T3952; Sigma Aldrich). Detailed procedures are 
available in the Supplementary Information. Confocal 
images were generated with a Leica TCS SP5 Confocal 
microscope (Leica Microsystems). For each sample, 
analyses of fluorescence intensities was performed in 
at least five randomly picked fields per condition using 
ImageJ software (imagej.nih.gov/ij) and experiments 
were repeated three or 6 times for monolayers cultures 
or GBM neurospheres, respectively. For Annexin V or 
Lysotracker quantification the fluorescence threshold 
was set, and the mean intensity of the fluorochrome was 
calculated and plotted in the graph. For proteins staining 
quantification, the area of the cells or the spheres was 
defined using a ROI as a boundary. We calculated the 
integrated intensity of the whole ROI. Detailed procedures 
can be found in the Supplementary Information section. 
Time-lapse microscopy experiments were performed using 
three primary GBM cell monolayers cultivated in stem 
cell permissive media in 48-wells plates. Briefly, GBM 
cultures at the second or third culturing passage were 
transfected with a control- or ATP6V1G1-directed siRNA 
(Sigma Aldrich) as described above, or left untreated. 
Then GBM cells were monitored over a period of 72 
hours for spheres formation using a time-lapse microscope 
(Eclipse Ti-E, Nikon Instruments, Florence, Italy). Images 
for each sample were snapped every two hours and then 
assembled to a movie in QuickTime format.
Statistical analysis
Groups’ comparisons were performed using 
unpaired two-sided Student’s t test (with Welch’s 
correction if groups had unequal variances) or Mann-
Whitney U test when appropriate (GraphPad Prism 
software, La Jolla, CA, USA). The significance of a 
variable for GBM patients’ prognosis was analyzed using 
the Cox regression hazard model either as univariate or 
multivariate analysis (MedCalc software, Mariakerke, 
Belgium) considering proteins IHC scores, MGMT 
methylation status, age at diagnosis, presence of IDH1R132H 
mutation or tumor grade as categorical variables. To 
generate a cut-off for V-ATPase G1 IHC score we used 
receiver operating characteristics (ROC) curves and the 
non-arbitrary criterion derived from the Youden index (J, 
MedCalc Software) as described [40]. Glioma patients 
were then sorted into low or high-expressor categories. 
The Kaplan Meier method was used to plot survival 
curves of glioblastoma patients. In TTP analysis patients’ 
death were censored. Difference in survival curves was 
computed using the Log Rank test (MedCalc Software). 
Two-sided P values less than 0.05 were considered 
statistically significant.
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